Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.56 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.56 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.56 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.51 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | RXRB | P28702 | 1/20 | 0.49 |
| ▸ | RXRG | P48443 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7921994 | 0.92 | KMT2A (0.58) | MEN1KMT2AMRGPRX4NR4A2NR4A1 | |
| SCHEMBL1842000 | 0.91 | MEN1 (0.56) | MEN1KMT2AMRGPRX4NR4A2NR4A1 | |
| SCHEMBL4499664 | 0.91 | MEN1 (0.56) | MEN1KMT2AMRGPRX4NR4A2NR4A1 | |
| SCHEMBL8057855 | 0.90 | MEN1 (0.55) | MEN1KMT2AMRGPRX4NR4A2NR4A1 | |
| SCHEMBL22490923 | 0.88 | MEN1 (0.54) | MEN1KMT2AMRGPRX4NR4A2NR4A1 | |
| SCHEMBL31643437 | 0.87 | MEN1 (0.52) | MEN1KMT2AMRGPRX4NR4A2NR4A1 | |
| SCHEMBL31643371 | 0.87 | MEN1 (0.52) | MEN1KMT2AMRGPRX4NR4A2NR4A1 | |
| SCHEMBL31643896 | 0.87 | MEN1 (0.52) | MEN1KMT2AMRGPRX4NR4A2NR4A1 | |
| SCHEMBL10073221 | 0.86 | HPGD (0.55) | MEN1KMT2AMRGPRX4NR4A2NR4A1 | |
| SCHEMBL31644137 | 0.85 | MEN1 (0.50) | MEN1KMT2AMRGPRX4NR4A2NR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228811-A1 | Triester Compounds And Methods Of Use Thereof | LIFEMINE THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2025137071-A2 | TRIESTER COMPOUNDS AND METHODS OF USE THEREOF | LIFEMINE THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-1951708-B1 | PIPERAZINE DERIVATIVE USEFUL AS A CCR5 ANTAGONIST | MERCK SHARP & DOHME (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-8048901-B2 | 5-{3-[3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-propyl}-2H-tetrazole; metabolic disorders, insulin resistance, dyslipidemia, Syndrome X | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-8048901-B2 | 5-{3-[3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-propyl}-2H-tetrazole; metabolic disorders, insulin resistance, dyslipidemia, Syndrome X | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| EP-1632479-B1 | Pharmaceutical compositions comprising CCR5 antagonizing piperazine derivatives | SCHERING CORP (US) | 2011-01-12 | — | — | EP | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-6689765-B2 | VIRICIDES; ANTIINFLAMMATORY AGENTS | SCHERING CORPORATION | 2004-02-10 | — | — | US | disclosed |
| US-20030069252-A1 | Piperazine derivatives useful as CCR5 antagonists | MERCK SHARP & DOHME CORP. | 2003-04-10 | — | — | US | disclosed |
| US-6391865-B1 | AIDS THERAPY; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; SKIN DISORDERS | SCHERING CORPORATION | 2002-05-21 | — | — | US | disclosed |
| EP-1175401-A1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066558-A1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| EP-0675940-B1 | POLYALKYL HYDROXYAROMATIC ESTERS AND FUEL COMPOSITIONS CONTAINING THE SAME | CHEVRON CHEM CO (US) | 2000-05-24 | — | — | EP | disclosed |
| EP-0658573-B1 | Mannich condensation products of polyalkylene hydroxyaromatic esters and fuel compositions containing the same | CHEVRON CHEM CO (US) | 1998-05-13 | — | — | EP | disclosed |
| US-5713966-A | ANTIDEPOSIT AGENTS | CHEVRON CHEMICAL COMPANY (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0658573-A2 | Mannich condensation products of polyalkylene hydroxyaromatic esters and fuel compositions containing the same | CHEVRON CHEMICAL COMPANY (US) | 1995-06-21 | — | — | EP | disclosed |
| US-5399178-A | Antideposit agents | CHEVRON CHEMICAL COMPANY (US) | 1995-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069252-A1 | Piperazine derivatives useful as CCR5 antagonists | CCR5, CCR2, CXCR3 | MEN1 4863/4885KMT2A 3178/4885MRGPRX4 113/4885 |
| US-20250228811-A1 | Triester Compounds And Methods Of Use Thereof | CYP46A1, CYP17A1, CYP27A1 | MEN1 2994/4885KMT2A 2874/4885MRGPRX4 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.